Your browser doesn't support javascript.
loading
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.
Lapin, Morten; Huang, Helen J; Chagani, Sharmeen; Javle, Milind; Shroff, Rachna T; Pant, Shubham; Gouda, Mohamed A; Raina, Anjali; Madwani, Kiran; Holley, Veronica R; Call, S Greg; Dustin, Derek J; Lanman, Richard B; Meric-Bernstam, Funda; Raymond, Victoria M; Kwong, Lawrence N; Janku, Filip.
Afiliação
  • Lapin M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Huang HJ; Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway.
  • Chagani S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Javle M; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Shroff RT; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Pant S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Gouda MA; Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ.
  • Raina A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Madwani K; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Holley VR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lanman RB; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Raymond VM; Guardant Health, Redwood City, CA.
  • Kwong LN; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Janku F; Guardant Health, Redwood City, CA.
JCO Precis Oncol ; 6: e2100197, 2022 02.
Article em En | MEDLINE | ID: mdl-35171660
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Inibidores Enzimáticos / DNA Tumoral Circulante / Isocitrato Desidrogenase Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: JCO Precis Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias dos Ductos Biliares / Colangiocarcinoma / Inibidores Enzimáticos / DNA Tumoral Circulante / Isocitrato Desidrogenase Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: JCO Precis Oncol Ano de publicação: 2022 Tipo de documento: Article